Concurrent hypereosinophilic syndrome and deep vein thrombosis after Pfizer‐BioNTech COVID‐19 vaccination: A case report
Abstract Herein, we report a case of eosinophilia syndrome and deep vein thrombosis presenting concurrently after the administration of the BNT162b2 mRNA‐based coronavirus disease 2019 (COVID‐19) vaccine. It is extremely rare to have both hypereosinophilic syndrome and deep vein thrombosis simultane...
Saved in:
| Main Authors: | Shungo Yano, Taiju Miyagami, Takayuki Furusaka, Nagamasa Kano, Toshio Naito |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2023-03-01
|
| Series: | Clinical Case Reports |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/ccr3.7001 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Biologic Agents in Idiopathic Hypereosinophilic Syndrome
by: Ourania Papaioannou, et al.
Published: (2025-04-01) -
The increasing incidence and prevalence of hypereosinophilic syndrome in the United Kingdom
by: Gema Requena, et al.
Published: (2021-12-01) -
Side effects of the Pfizer BioNTech vaccine in health workers of a hospital in the southeast of Mexico
by: Jesús Arturo Ruiz-Quiñones, et al.
Published: (2022-09-01) -
Delayed-onset anaphylaxis after first dose of Pfizer-BioNTech COVID-19 vaccine
by: Carol Tay, et al.
Published: (2023-09-01) -
Lymphocytic Variant Hypereosinophilic Syndrome: Case Series From a Tertiary Referral Center in Canada
by: Xiu Qing Wang, et al.
Published: (2025-04-01)